
The Anecortave Acetate Risk Reduction Trial has met its patient enrollment requirement with almost 2,600 individuals who are at high risk for developing choroidal neovascularization (CNV) or advanced age-related macular degeneration (AMD) over time, reported Jason Slakter, MD, at a retina free papers session during the American Academy of Ophthalmology annual meeting.
